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Objectives This study sought to assess the presence of a dose-response effect of cigarette smoking and its
impact on high on-treatment platelet reactivity (HPR) in patients with diabetes mellitus treated with clopidogrel.
Background Cigarette smoking is an inducer of cytochrome P450 1A2, a hepatic enzyme involved
in clopidogrel metabolism. If cigarette smoking is associated with a dose-response effect on phar-
macodynamic measures in clopidogrel-treated patients is unknown.
Methods A total of 134 type 2 diabetes mellitus patients on maintenance aspirin and clopidogrel ther-
apy were studied. Patients were divided into 3 groups according to cotinine levels: 3 ng/ml (nonsmok-
ers), 3 to 199 ng/ml (light smokers), and 200 ng/ml (heavy smokers). Platelet function was assessed by
ight transmittance aggregometry, VerifyNow P2Y12 assay (Accumetrics, San Diego, California), and vaso-
ilator-stimulated phosphoprotein. Rates of HPR were deﬁned using established cutoff values.
esults A dose-response effect was observed for all pharmacodynamic parameters tested. Serum coti-
ine levels were inversely associated with platelet reactivity as assessed by light transmittance ag-
regometry using 5 and 20 mol/l adenosine diphosphate (p  0.0001 for all). Accordingly, platelet
disaggregation increased with levels of serum cotinine (p  0.0001). Similar results were found with
P2Y12 reaction units (p  0.0001) and inhibition of platelet aggregation (p  0.005) as deﬁned by
VerifyNow P2Y12 testing, and platelet reactivity index (p  0.002) as assessed by vasodilator-stimulated
phosphoprotein. Higher serum cotinine levels were signiﬁcantly associated with lower rates of HPR, as
deﬁned according to various pharmacodynamic cutoff measures.
Conclusions Cigarette smoking is associated with a dose-response effect on clopidogrel-induced
antiplatelet effects and lower rates of HPR in diabetes mellitus patients. (J Am Coll Cardiol Intv
2012;5:293–300) © 2012 by the American College of Cardiology Foundation
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294Numerous investigations have shown a broad variability in
clopidogrel-induced antiplatelet effects, and patients with
high on-treatment platelet reactivity (HPR) have an in-
creased risk of recurrent atherothrombotic events (1,2).
Multiple factors have been associated with the degree of
platelet inhibition induced by clopidogrel. Among these,
genetic and environmental factors modulating hepatic me-
tabolism of clopidogrel appear to have a pivotal role (1,2).
Clopidogrel is a prodrug that requires a 2-step oxidation by
cytochrome P450 (CYP) isoenzymes to generate an active
metabolite that in turn irreversibly inhibits the platelet
P2Y12 receptor (3). Cigarette
smoking is a known inducer of
CYP1A2, which is the predom-
inant isoenzyme responsible for
the first oxidative step in the
conversion of clopidogrel into its
active metabolite (4,5). Pharma-
codynamic (PD) and clinical
studies have shown that smokers
treated with clopidogrel have
enhanced platelet inhibition and
derive higher relative benefit, as
assessed by angiographic and clin-
ical outcomes, than nonsmokers
do (6–9). However, these studies
identified the aforementioned ef-
fects in smokers consuming above
a certain threshold of number of
cigarettes and were not able to
determine a dose-response effect
in a continuous way. This may be
attributed to the fact that these
investigations were based on self-
reported smoking, which is not an
objective measure of the amount
of nicotine exposure, as it depends
for instance on the type and brand
of cigarettes and smokers’ habit
(e.g., deep inhalation). In addi-
tion, because baseline characteris-
tics are associated with variations
in clopidogrel metabolism, it can-
not be excluded that patient selection may have had an impact
on these findings.
In the present investigation, the impact of cigarette
smoking on clopidogrel-induced antiplatelet effects was
assessed by means of a more objective assessment based on
levels of serum cotinine, the major stable degradation
product of nicotine metabolism (10). Because clopidogrel
metabolism is reduced among patients with diabetes melli-
tus (DM), which may contribute to their high prevalence of
HPR while on clopidogrel therapy (11), this population was
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CI  confidence interval
CYP  cytochrome P450
DM  diabetes mellitus
HPR  high on-treatment
platelet reactivity
IPA  inhibition of platelet
aggregation
LPA  late values of
on-treatment platelet
aggregation
LTA  light transmittance
aggregometry
MFI  mean fluorescence
intensity
MPA  maximal values of
on-treatment platelet
aggregation
OR  odds ratio
PD  pharmacodynamic
PGE1  prostaglandin E1
PRI  platelet reactivity
index
PRP  platelet-rich plasma
PRU  P2Y12 reaction units
VASP-P  phosphorylation of
vasodilator-stimulated
phosphoproteinidentified to test our study hypothesis. The aim of thepresent investigation was to assess if there is a dose-response
effect of cigarette smoking, as assessed by serum cotinine
levels, and how this affects rates of HPR in patients with
DM on maintenance clopidogrel therapy.
Methods
Patient population. The present investigation is a cross-
ectional observational study that evaluated the association
etween cigarette smoking and PD effects of clopidogrel. A
atabase of patients who had undergone platelet function
ssessments at our Thrombosis Research Laboratory (Uni-
ersity of Florida College of Medicine–Jacksonville) be-
ween 2006 and 2010 was used to identify eligible subjects
or this investigation. Patients meeting study inclusion
riteria, who also had a serum sample collected at the time
f platelet function assessment to enable cotinine measure-
ent, were identified. All patients had undergone percuta-
eous coronary intervention with stent implantation and
ere treated with dual antiplatelet therapy per standard of
are. In particular, patients were eligible for the study if they
ad type 2 DM and were clinically stable while on mainte-
ance dual antiplatelet therapy with aspirin (81 mg daily)
nd clopidogrel (75 mg daily) for at least 1 month. Patients
eeded to be on maintenance dual antiplatelet therapy for at
east 1 month as prior investigations have shown that
latelet reactivity is subject to variability in the earlier phases
f treatment and reaches a steady-state phase following 1
onth of therapy (12–14). Type 2 DM patients also needed
o have been medically managed (oral or insulin therapy) for
t least 2 months without changes in hypoglycemic treat-
ent regimen. General major exclusion criteria included:
nown allergies to aspirin or clopidogrel; left ventricular
jection fraction 30%; blood dyscrasia; active bleeding or
leeding diathesis; gastrointestinal bleed within last 6
onths; hemodynamic instability; cerebrovascular accident
ithin 3 months; any malignancy; concomitant use of other
ntithrombotic drugs (oral anticoagulants, dipyridamole,
iclopidine, or cilostazol); recent treatment (30 days) with
glycoprotein IIb/IIIa antagonist; platelet count 100 
103/l; liver disease (baseline alanine transaminase 2.5
the upper limit of normal).
Patients were recruited at the Division of Cardiology of
the University of Florida College of Medicine–Jacksonville.
The study complied with the Declaration of Helsinki and
was approved by the Institutional Review Board of the
University of Florida College of Medicine–Jacksonville. All
subjects provided written informed consent for platelet
function assessments and for storage of serum samples. The
authors had full access to the data and take full responsibility
for its integrity. All authors have read and agreed to the
manuscript as written.
Blood sampling and functional assessments. Peripheral ve-
nous blood samples were drawn with a loose tourniquet to
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295avoid artifacts through a short venous catheter inserted into
a forearm vein. Samples were collected before administra-
tion of the morning dose of clopidogrel (trough levels). The
first 2 to 4 ml of blood was discarded to avoid spontaneous
platelet activation. Samples were processed within 1 h after
blood drawing.
Light transmittance aggregometry. Platelet aggregation was
performed using light transmittance aggregometry (LTA)
according to standard protocols (15–17). In brief, platelet
aggregation was assessed using platelet-rich plasma (PRP)
by the turbidimetric method in a 2-channel aggregometer
(Chrono-Log 490 Model, Chrono-Log Corp., Havertown,
Pennsylvania). PRP was obtained as a supernatant after
centrifugation of citrated blood at 800 revolutions/min for
10 min. The isolated PRP was kept at 37°C before use.
Platelet-poor plasma was obtained by a second centrifuga-
tion of the blood fraction at 2,500 revolutions/min for 10
min. Light transmission was adjusted to 0% with PRP and
to 100% for platelet-poor plasma for each measurement and
assessed following challenge with adenosine diphosphate
(ADP) (5 and 20 mol/l) (15–17). Maximal (MPA) and
ate (LPA) values of on-treatment platelet aggregation were
easured. Percentage of platelet disaggregation was derived
rom MPA and LPA values [disaggregation (%)  100 
1 – LPA/MPA)], as previously defined (15,16).
VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay (Ac-
umetrics, San Diego, California) is a rapid whole-blood
oint-of-care assay and was used according to the instruc-
ions of the manufacturer (16,17). The VerifyNow P2Y12
ssay reports the results as P2Y12 reaction units (PRU). This
ssay mimics turbidimetric aggregation and uses disposable
artridges containing 20 mmol/l ADP and 22 nmol/l
rostaglandin E1 (PGE1). Aggregation testing using ADP
s a sole agonist activates P2Y1 and P2Y12 purinergic
signaling, whereas adding PGE1 increases the specificity of
the test for P2Y12 signaling. In a separate channel of the
cartridge in which iso-TRAP is used as an agonist, a
baseline value for platelet function is obtained, enabling
assessment of inhibition of platelet aggregation (IPA) with-
out having to wean the patient off antiplatelet treatment.
P2Y12 reactivity index. The platelet reactivity index (PRI)
was calculated as a measure of the functional status of the
P2Y12 signaling pathway. PRI was determined through
ssessment of phosphorylation status of vasodilator-
timulated phosphoprotein (VASP-P), a key, specific intra-
latelet mediator of P2Y12 signaling, according to standard
protocols (15–17). In brief, VASP-P was measured by
quantitative flow cytometry (Beckman Coulter FC500,
Miami, Florida) using commercially available labeled
monoclonal antibodies (Biocytex Inc., Marseille, France).
The PRI was calculated after measuring the mean fluores-
cence intensity (MFI) of VASP-P levels following challenge
with PGE1 and PGE1 plus ADP. PGE1 increases VASP-P
levels through stimulation of adenylate cyclase, whereas ADPbinding to purinergic receptors leads to inhibition of adenylate
cyclase. Therefore, the addition of ADP to PGE1-stimulated
latelets reduces levels of PGE1-induced VASP-P. The PRI
was calculated as follows: ([MFI PGE1] – [MFI PGE1 
ADP]/[MFI PGE1])  100. Elevated PRI values indicate
p-regulation of the P2Y12 signaling pathway (15–17).
Cotinine measurement. Cotinine levels were measured as a
nal batch assessment using stored serum samples collected
t the time of platelet function assessment using the
otinine Blood Test kit (Calbiotech, Spring Valley, Cali-
ornia), a solid phase competitive enzyme-linked immuno-
dsorbent assay, as previously described (18). The samples
nd cotinine enzyme conjugate are added to the wells coated
ith anticotinine antibody. Cotinine in the samples com-
etes with a cotinine enzyme conjugate for binding sites.
nbound cotinine and cotinine enzyme conjugate is washed
ff by a washing step. With the addition of the substrate, the
ntensity of color is inversely proportional to the concentra-
ion of cotinine in the samples obtained with the cotinine
lood test. A standard curve is prepared relating color
ntensity to the concentration of the cotinine (18).
Deﬁnitions. Patients were divided into 3 groups according
o serum cotinine levels measured by the cotinine enzyme-
inked immunoadsorbent assay test. Serum cotinine levels
3, 3 to 199, and 200 ng/ml indicated nonsmoker, light
moker, and heavy smoker status, respectively (19–21).
HPR was defined using various previously defined cutoff
evels that have been associated with an increased risk of
ecurrent ischemic events (1,15,22,23). These included the
ollowing cutoff values using LTA: MPA-ADP (20 mol/l)
50% and MPA-ADP (5 mol/l)46%; VerifyNow P2Y12
assay: PRU 230 and IPA 40%; and VASP: PRI 50%.
Statistical analysis. Continuous variables were analyzed for
a normal distribution with the Kolmogorov-Smirnov test
and presented as mean SD or as median and interquartile
range if a normal distribution was present or not, respec-
tively. Student t test or Mann-Whitney U test were used for
comparisons of continuous variables where appropriate.
Categorical variables are expressed as frequencies and per-
centages. Categorical variables were tested using the chi-
square test or Fisher exact test when at least 25% of values
showed an expected cell frequency below 5. Analysis of
variance with post hoc Bonferroni correction was used to
compare continuous variables among more than 2 groups
and correct for multiple comparisons. In addition, p values
for trend when assessing platelet reactivity according to the
smoking degree, which was considered as a categorical
variable with an ordinal scale, were performed with a
polynomial contrast with analysis of variance method, using
median values of each category as coefficients. Comparisons
between categorical variables were performed using McNe-
mar test or binomial exact test. Control for potential
confounders and analysis of independent correlates of HPR
were performed with a logistic regression model, including
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296age, insulin treatment, body mass index, creatinine 1.5
mg/dl, hemoglobin A1C, use of statin, and proton pump
inhibitors as covariates, and the degree of smoker (non-,
light, or heavy smoker) as the independent categorical
variable of interest, using nonsmoker as the reference
category. Odds ratio (OR) and 95% confidence interval (CI)
were calculated. All univariate variables p  0.1 and those
deemed of clinical interest were included in the statistical
model. All probability values reported are 2-sided, and a
value of p  0.05 was considered significant. Statistical
analysis was performed with SPSS software (version 15.0,
SPSS Inc., Chicago, Illinois).
Results
A total of 134 type 2 DM patients with stable coronary
artery disease on aspirin and clopidogrel therapy meeting
study inclusion criteria were identified for this investigation.
A total of 49 patients (37%) were active smokers. Patients
were divided into 3 groups according to serum cotinine
levels: 3 ng/ml (nonsmoker; n  85), 3 to 199 ng/ml
(light smoker; n  27), and 200 ng/ml (heavy smoker;
n  22). Baseline demographics and clinical characteristics
Table 1. Baseline Demographics and Clinical Characteristics
Nonsmoker
(n  85)
Light
Smoker
(n  27)
Heavy
Smoker
(n  22) p Value
Age, yrs 62.3 9.0 64.0 9.1 57.6 9.1 0.04
Male 41 (48) 16 (59) 13 (59) 0.47
Race 0.67
Caucasian 52 (61) 20 (74) 16 (73)
African American 29 (34) 6 (22) 5 (23)
Hispanic 2 (2) 0 1 (5)
Asian 2 (2) 1 (4) 0 (0)
Risk factors/medical history
Hyperlipidemia 79 (95) 25 (93) 20 (91) 0.72
Hypertension 82 (97) 27 (100) 22 (100) 0.41
Creatinine 1.5 mg/dl 11 (13) 3 (11) 0 (0) 0.35
Body mass index, kg/m2 34.7 7.7 31.7 6.7 32.1 7.7 0.13
Hemoglobin A1C 7.7 2.3 7.4 1.5 7.6 1.7 0.89
Prior myocardial infarction 50 (59) 16 (59) 18 (82) 0.13
Prior CABG 26 (31) 10 (37) 3 (14) 0.18
Prior stroke 5 (6) 2 (7) 2 (9) 0.87
Treatment
Beta-blockers 71 (84) 21 (78) 15 (68) 0.27
Nitrates 27 (32) 10 (37) 7 (32) 0.87
ACE inhibitors/ARB 75 (88) 20 (74) 17 (77) 0.15
PPI 21 (25) 7 (26) 5 (23) 0.97
Statin 79 (93) 23 (85) 17 (77) 0.09
Insulin therapy 35 (41) 7 (26) 8 (36) 0.36
Values are mean SD or n (%).
ACEangiotensin-convertingenzyme;ARBangiotensinIIreceptorblockers;CABGcoronaryartery
bypassgraft; PPIprotonpump inhibitors.of the study population are provided in Table 1. Patientswere similar for all baseline characteristics, except for a
lower age in the heavy smoker group (p  0.04).
A dose-response effect was observed for all pharmacody-
namic parameters tested. Serum cotinine levels were in-
versely associated with levels of on-treatment platelet reac-
tivity as assessed by LTA for both MPA and LPA values
using 5 and 20 mol/l ADP (p for trend 0.0001) (Fig. 1).
Accordingly, platelet disaggregation increased with levels of
serum cotinine (p for trend 0.0001; both 5 and 20 mol/l
ADP; data not shown). Similarly to the LTA findings,
results obtained with the VerifyNow P2Y12 assay also
showed a dose-response effect as measured by PRU (p for
trend 0.0001) and IPA (p for trend  0.002) values (Fig. 2).
Ultimately, enhanced clopidogrel-induced antiplatelet ef-
fects with increased cotinine levels were observed using flow
cytometric assessment of VASP to define PRI values (p for
trend  0.001) (Fig. 3).
 ADP 5 μmol/l  MPA  ADP 5 μmol/l  LPA  
p for trend <0.0001 p for trend <0.0001 
p=0.003 
p<0.0001 
p=0.005 
(%) (%) 
p<0.0001 
 ADP 20  μmol/l  MPA   ADP 20  μmol/l  LPA  
p for trend <0.0001 p for trend <0.0001 
p=0.014 
p<0.0001 p<0.0001 
p=0.031 
(%) (%) 
Figure 1. Platelet Reactivity Assessed by LTA According to the
Degree of Smoking Defined by Cotinine Levels
Impact of the degree of smoking status to clopidogrel-induced antiplatelet
effects on maximum and late 5 mol/l and 20 mol/l adenosine diphos-
phate (ADP)-induced platelet aggregation. Error bars indicate standard
deviations of the mean. LPA  late value of on-treatment platelet aggrega-
tion; LTA  light transmittance aggregometry; MPA  maximal value of
on-treatment platelet aggregation.
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297The prevalence of HPR in the overall study population
varied according to the definition used: MPA-ADP (20
mol/l): 69%; MPA-ADP (5 mol/l): 39%; PRU: 48%;
PA: 67%; PRI: 73%. Higher serum cotinine levels were
ignificantly associated with lower rates of HPR as defined
ccording to all pharmacodynamic cutoff measures (Fig. 4).
A multivariable logistic regression analysis showed that,
ompared with nonsmokers, light (adjusted OR: 0.24, 95%
I: 0.074 to 0.76, p  0.015) and heavy smokers (adjusted
R: 0.10, 95% CI: 0.027 to 0.37, p 0.001) were less likely
o have HPR as assessed by LTA following 20 mol/l ADP
stimuli. Similar results were found with 5 mol/l ADP
timuli (light smokers: adjusted OR: 0.47, 95% CI: 0.16 to
.37, p  0.17; heavy smokers: adjusted OR: 0.051, 95%
I: 0.006 to 0.43, p  0.006), PRU values (light smokers:
djusted OR: 0.23, 95% CI: 0.063 to 0.85, p 0.027; heavy
mokers: adjusted OR: 0.24, 95% CI: 0.052 to 1.08, p 
.063), IPA (light smokers: adjusted OR: 0.21, 95% CI:
.062 to 0.73, p 0.014; heavy smokers; adjusted OR: 0.14, 95%
CI: 0.034 to 0.58, p  0.006), and PRI values (light
smokers: adjusted OR: 0.25, 95% CI: 0.067 to 0.94, p 
0.039; heavy smokers; adjusted OR: 0.24, 95% CI: 0.055 to
1.03, p  0.054).
Discussion
Cigarette smoking has emerged as a factor associated with
improved clopidogrel effects. This is supported by PD
investigations as well as clinical outcome studies demon-
strating better clopidogrel effects among smokers versus
nonsmokers (6–9). However, to date, investigations have
been based on self-reported smoking, which is a nonobjec-
A) P2Y12 Reaction Unit 
p for trend <0.0001 
p=0.001 
p=0.018 
P2
Y
12
 re
ac
tio
n 
un
its
 (P
R
U
) 
Figure 2. Platelet Reactivity Assessed by the VerifyNow P2Y12 Assays Acc
Impact of the degree of smoking status to clopidogrel-induced antiplatelet eff
(B). Error bars indicate SD of the mean. VerifyNow P2Y12 assays are a producttive way to quantify nicotine exposure. In turn, even thoughthese seminal investigations were able to consistently define
a threshold of smoking at least one-half pack/day to
significantly affect the efficacy of clopidogrel, they were not
able to ascertain the presence of a dose-response effect
among smokers (6–9). Cotinine is the major degradation
product of nicotine metabolism and has a serum half-life of
about 17 h (being detectable up to 3 days after withdrawal),
and its levels correlate with the amount of nicotine exposure
(i.e., severity of smoking habit) (10). To the best of our
knowledge, the present investigation is the first PD study to
examine and demonstrate the presence of a dose-response
effect of smoking on clopidogrel effects by using a more
objective measure to quantify cigarette smoking as deter-
mined by assessing serum cotinine levels. In addition to
demonstrating the impact of cotinine levels on the degree of
platelet reactivity, our study showed a dose-response profile
on the prevalence of rates of HPR. Importantly, our
findings were consistent using multiple PD parameters and
confirmed in multivariate analysis, which provided support
to our study hypothesis.
Multiple factors have been associated with interindividual
response profiles to clopidogrel therapy (1,2). Cigarette
smoking has been recently added to the factors associated
with improved clopidogrel effects (6–9). The enhanced PD
effects observed among smokers and the lower prevalence of
HPR, defined according to cutoff values associated with
recurrent atherothrombotic events, can explain why these
subjects derive more benefit from clopidogrel in preventing
ischemic events than nonsmokers do (7–9). The enhanced
platelet inhibitory effects induced by clopidogrel among
smokers can also contribute to their increased potential for
B) Inhibition of platelet aggregation 
p for trend =0.002 
p=0.005 %) 
p=0.068 
g to the Degree of Smoking Defined by Cotinine Levels
n P2Y12 reaction units (PRU) (A) and inhibition of platelet aggregation (IPA)
umetrics (San Diego, California).(
ordin
ects obleeding complications (9,24). Reduced ischemic event rates
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298and increased spontaneous bleeding have also been demon-
strated with novel P2Y12 inhibitors characterized by more
potent PD effects (25,26). Several factors can explain the
“smoker’s paradox” observed among clopidogrel-treated pa-
tients. Cigarette smoking is a known inducer of CYP1A2,
which is the predominant isoenzyme responsible for the first
oxidative step in the conversion of clopidogrel into its active
metabolite (3). Therefore, accelerating the first step of clopi-
dogrel biotransformation would help prevent it from being
shunted toward esterases mediating transformation into inac-
tive metabolites (8). Importantly, CYP1A2 activity increases
relative to the number of cigarettes smoked per day (27), which
may explain the dose-response effect observed in our study.
Investigations have shown that smokers have higher
P2Y12 expression in platelet lysates than nonsmokers do
28). Therefore, it may be hypothesized that a high platelet
urface P2Y12 density may contribute to an increased risk of
ecurrent ischemic events among smokers, which can po-
entially be suppressed to a relatively greater extent by
lopidogrel. Indeed, it may be argued that although several
linical studies assessing adjunctive treatment with clopi-
ogrel in addition to aspirin in high-risk patients showed a
reater relative clinical benefit in smokers than in nonsmok-
rs (7–9), others have not (29). Differences in patient character-
Figure 3. Platelet Reactivity Assessed by Phosphorylation Status of
VASP According to the Degree of Smoking Defined by Cotinine Levels
Impact of the degree of smoking status to clopidogrel-induced antiplatelet
effects on platelet reactivity index (PRI). Error bars indicate standard devia-
tions of the mean. VASP  vasodilator-stimulated phosphoprotein.stics may contribute to these discrepancies as numerouslinical characteristics have shown to affect clopidogrel
etabolism and ultimately its PD effects (1,2). The present
nvestigation was selectively conducted in patients with DM,
nown to have high rates of HPR (15–17,30–33). Studies have
hown that this may be attributed to reduced metabolic
ctivity of the CYP system in DM patients, which in turn
enerates lower levels of active metabolites than are found in
on-DM patients (11). Therefore, including a population,
uch as patients with DM, with reduced CYP metabolic
ctivity can increase the likelihood of identifying a dose-
esponse effect when analyzing the impact of a CYP
nducer, such as cigarette smoking. In line with this obser-
ation, recent findings have shown that the smokers’ para-
ox is limited only to patients with a specific CYP1A2 genotype
(34). However, the latter investigation did not discriminate the
intensity of smoking in their patient population.
Despite the fact that clopidogrel effects are enhanced in
smokers versus nonsmokers, cardiovascular event rates, in-
cluding mortality, still remain markedly higher among
smokers irrespective of type of antiplatelet treatment regi-
men used (35). Smoking is a major risk factor for athero-
thrombotic cardiovascular processes and smoking cessation
is a class I recommendation for secondary prevention of
ischemic events in patients with vascular disease (36).
Whereas the optimal healthcare saving goal to reduce
atherothrombotic risk is smoking cessation, this objective is
not always achieved and many patients with established
atherosclerotic disease continue smoking. Therefore, defin-
ing the optimal antiplatelet treatment strategy in these
patients becomes of key importance. This is particularly
relevant to those patients who do not have a clinical
indication to be on dual antiplatelet therapy with aspirin and
clopidogrel therapy according practice guidelines and who
rely on a single antiplatelet agent, mostly aspirin, for their
antithrombotic protection. Head-to-head comparisons be-
tween aspirin and clopidogrel for secondary prevention of
recurrent ischemic events showed clopidogrel to be only
marginally better than aspirin in the CAPRIE (Clopidogrel
Versus Aspirin in Patients at Risk of Ischemic Events) trial
(37). The benefit of clopidogrel was increased in higher risk
subgroups, including patients with DM (38,39). Although,
dedicated comparative assessments in smokers versus non-
smokers are lacking in this study, it may be hypothesized
that aspirin may offer less antithrombotic protection than
clopidogrel does, particularly in smokers. In fact, given the
increased density of P2Y12 receptors among smokers, clopi-
dogrel may be a more effective platelet inhibitor (28).
Therefore, understanding the differences in antithrombotic
effects of aspirin compared with clopidogrel among smokers
may help define the antiplatelet agent of choice when single
therapy is indicated.
Study limitations. The present investigation is a cross-
sectional observational study that evaluated the association
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299between cigarette smoking and PD effects of clopidogrel. A
longitudinal study in which PD effects are measured in the
same patient in the presence and absence of active cigarette
smoking is needed to confirm a causative relationship
between cigarette smoking and enhanced clopidogrel anti-
platelet effects. The present investigation did not include
pharmacokinetic assessments to determine clopidogrel ac-
tive metabolite levels. In addition, the effects of smoking
were not stratified according to individuals’ genotype. The
impact of cigarette smoking on pharmacokinetic and PD
assessments, as well as if these may be affected by genotypes,
is currently being investigated in a dedicated prospective
trial (The Influence of Smoking Status on Prasugrel and
Clopidogrel Treated Subjects Taking Aspirin and Having
Stable Coronary Artery Disease; NCT01260584) that will
provide further insights into this topic. A possible limitation
of the present investigation is an overfitted covariate-
adjusted model. However, in order to avoid spurious asso-
ciations, we included in the analysis those variables that
could represent potential confounders for the present anal-
ysis, as specified in the statistical analysis section.
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